今日早参 2026 年 3 月 25 日 何康 策略首席研究员兼金融工程首席研究 员 座机：021-28972202 邮箱：hekang@htsc.com 王玮嘉 公用事业环保行业首席研究员 座机：021-28972079 邮箱：wangweijia@htsc.com 今日热点 策略：资金透视：配置型资金仓位转向防御 尽管外围风险此前已有演绎，但交易型资金在前期表现出较强的持仓惯性， 上周投资者对地缘政治定价提升，市场波动率放大，上周五融资资金单日净 流出超 150 亿标志着资金情绪出现回落，触发融资融券的去杠杆进程，担保 比例从 290%的历史高位迅速回落至 278%的年初水平，后续进一步出清需观 察融资去杠杆幅度；其次，存量资金的结构博弈正由"进攻"转向"防御避 险"。在不确定性升温的背景下，配置型资金的审美发生了显著转移：测算 数据显示，基金仓位出现向消费、金融等方向腾挪的倾向，资金开始在防御 性品种中寻找新的安全边际。此外，宽基 ETF 在净流出 9 周后转向小幅净流 入，上周宽基 ETF 净流入 95 亿元。 风险提示：1）估算持仓模型失效；2）数据统计口径有误。 闫萌 SAC:S057052512 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Views - The medical consumables sector saw a 1.94% increase last week, with the sector's performance being relatively stable compared to other healthcare segments [4][12] - The current PE ratio for the medical consumables sector is 36.85X, which has increased by 0.68X from the previous week, while the PB ratio stands at 2.66X [5][20] - Key companies in the sector, such as Huatai Medical and Sainuo Medical, reported significant revenue growth, indicating a positive trend in the industry [6][23] Summary by Sections Industry Performance - The medical consumables sector reported a closing index of 6047.08 points, reflecting a 1.94% increase [4] - Over the past month, the sector has shown a relative return of 2%, while the absolute return over the last 12 months is 18% [3][4] Valuation Metrics - The PE ratio for the medical consumables sector is currently at 36.85X, with a one-year maximum of 40.1X and a minimum of 28.88X [5][17] - The PB ratio is at 2.66X, with a one-year maximum of 2.92X and a minimum of 2.13X [20] Industry Dynamics and Company Announcements - Huatai Medical reported a revenue of 258,392.73 million yuan for 2025, a 25.08% increase year-on-year, with a net profit of 82,063.66 million yuan, up 21.91% [6][22] - Sainuo Medical achieved a total revenue of 52,540.79 million yuan, a 14.53% increase year-on-year, with a net profit of 4,728.63 million yuan, reflecting a significant growth of 3,057.05% [6][23] Investment Recommendations - The report suggests focusing on high-value consumables companies that are showing performance reversals and have strong innovation capabilities, such as Huatai Medical and Microneurophysiology [7][26] - The report emphasizes the importance of companies that can control costs and innovate in a competitive environment, particularly in the orthopedic consumables sector [7][26]

Summary of Huatai Medical's Earnings Call Company Overview - **Company**: Huatai Medical - **Fiscal Year**: 2025 Key Financial Metrics - **Revenue**: - 2025 revenue reached 2.584 billion CNY, representing a year-over-year increase of 25.1% [1] - **Net Profit**: - Net profit attributable to shareholders was 821 million CNY, up 21.9% year-over-year [1] - **Net Profit (Excluding Non-recurring Items)**: - Net profit excluding non-recurring items was 791 million CNY, reflecting a 23.0% increase year-over-year [1] - **Quarterly Performance (Q4 2025)**: - Q4 revenue was 716 million CNY, a year-over-year increase of 32.4% and a quarter-over-quarter increase of 9.6% [1] - Q4 net profit attributable to shareholders was 197 million CNY, up 36.1% year-over-year but down 0.4% quarter-over-quarter [1] - Q4 net profit (excluding non-recurring items) was 189 million CNY, showing a year-over-year increase of 39.9% but a quarter-over-quarter decrease of 1.4% [1] Profitability Ratios - **Net Profit Margin**: - The net profit margin for Q4 was 27.5%, an increase of 0.74 percentage points year-over-year but a decrease of 2.77 percentage points quarter-over-quarter [2] - The net profit margin (excluding non-recurring items) was 26.3%, up 1.41 percentage points year-over-year but down 2.95 percentage points quarter-over-quarter [2] Operational Insights - **Market Expansion**: - The company has been actively deepening market development through various promotional activities, leveraging R&D, technology, quality, and market channels to enhance product coverage and admission rates [3] - **Cost Control**: - Emphasis on cost management with R&D and sales expenses focused on core products like PFA, clinical validation, and next-generation product development [3] - Achieved synergy between net profit and revenue through refined operations and optimized expenditure structure [3] Additional Notes - The company's performance aligns with prior forecasts, which anticipated revenue growth of 20-30% and net profit growth (both attributable and excluding non-recurring items) of 15-25% [1]

Group 1 - The company reported a revenue of 258,392.73 million RMB for the reporting period, representing a growth of 25.08% compared to the same period last year [3] - The net profit attributable to the parent company's owners was 82,063.66 million RMB, an increase of 21.91% year-on-year [3] - The net profit after deducting non-recurring gains and losses was 79,087.59 million RMB, reflecting a growth of 23.00% compared to the previous year [3] - The total assets at the end of the reporting period amounted to 365,185.66 million RMB, which is a 22.52% increase from the beginning of the reporting period [3] Group 2 - The company implemented a capital reserve conversion plan during the reporting period, resulting in a 44.80% increase in share capital, with a distribution of 4.5 shares for every 10 shares held [4] - The growth in operating performance was attributed to continuous market expansion efforts, effective marketing activities, and a focus on core products such as PFA [3] - The company emphasized cost control, directing R&D and sales expenses towards market promotion and clinical validation of core products, optimizing expenditure structure and achieving synchronized growth in net profit and revenue [3]

Core Viewpoint - Huatai Medical (688617.SH) reported a revenue of 2.584 billion yuan for the year 2025, representing a year-on-year growth of 25.08%, and a net profit attributable to the parent company of 821 million yuan, with a year-on-year increase of 21.91% [1] Group 1: Financial Performance - The company achieved a revenue of 2.584 billion yuan in 2025, marking a 25.08% increase compared to the previous year [1] - The net profit attributable to the parent company reached 821 million yuan, reflecting a growth of 21.91% year-on-year [1] Group 2: Factors Influencing Performance - The main reasons impacting operational performance include the company's ongoing market expansion efforts and various promotional activities, leveraging advantages in R&D, technology, quality, market, and channels to enhance product coverage and hospital admission rates [1] - The company emphasizes cost control, focusing R&D and sales expenses on the market promotion, clinical validation, and iterative development of core products like PFA, optimizing expenditure structure and rhythm through refined operations and scaled operations to achieve synchronized growth in net profit and revenue [1]

报告期内影响经营业绩的主要原因：（1）公司持续深化市场开拓，持续开展各类市场推广活动，积极 发挥研发、技术、质量、市场、渠道等多方面经营优势，不断加深渠道联动，实现产品覆盖率及入院率 的进一步提升；（2）公司始终重视费用管控，研发及销售费用投入聚焦于PFA等核心产品的市场推 广、临床验证及下一代产品研发迭代，通过精细化运营、规模化运行，优化开支结构与节奏，实现净利 润与营收的协同增长。 格隆汇2月26日丨惠泰医疗(688617.SH)公布2025年度业绩快报，报告期内，公司实现营业收入25.84亿 元，较上年同期增长25.08%；归属于母公司所有者的净利润8.21亿元，较上年同期增长21.91%；归属于 母公司所有者的扣除非经常性损益的净利润7.91亿元，较上年同期增长23.00%； ...

Core Viewpoint - Yonghe Co., Ltd. (605020.SH) is expected to achieve a significant increase in net profit for 2025, with projections indicating a growth of 110.87% to 150.66% year-on-year, driven by a high demand in the refrigerant industry and the company's operational efficiencies [1][3]. Financial Performance - The projected net profit attributable to shareholders for 2025 is estimated to be between 530 million to 630 million yuan, an increase of 279 million to 379 million yuan compared to the previous year [3]. - For the first three quarters of 2025, the company reported a revenue of 3.786 billion yuan, reflecting a year-on-year growth of 12.04%, and a net profit of 469 million yuan, which is a 220.39% increase [2][3]. - The total assets of Yonghe Co., Ltd. reached 7.904 billion yuan by the end of September 2025, with a debt-to-asset ratio of 28.48%, marking a five-year low [1][6]. Industry Position and Product Offering - Yonghe Co., Ltd. operates in the fluorochemical sector, with a comprehensive product chain that includes fluorite resources, hydrofluoric acid, fluorocarbon chemicals, and fluorine-containing polymers [2]. - The company has established a global sales network covering over 100 countries and regions, supported by its brands "Ice Dragon" and "Fluorlon" [2]. Operational Efficiency and Competitive Advantage - The company benefits from a complete industrial chain that enhances production organization and resource allocation, leading to improved profitability [4]. - Yonghe Co., Ltd. has a production capacity of 190,000 tons for fluorocarbon chemicals and 82,800 tons for fluorine-containing polymer materials, with significant market positions in key products [5][6]. Research and Development - The company emphasizes a strategy of independent research and development, with a focus on high-end and green fluorochemical demands, resulting in 78 valid patents as of mid-2025 [7]. - R&D expenditures have consistently increased, with amounts of 52.11 million yuan, 90.23 million yuan, 104 million yuan, and 81.6 million yuan from 2022 to the first three quarters of 2025, reflecting a commitment to innovation [7].

Group 1 - The company expects a net profit attributable to shareholders for 2025 to be between 530 million to 630 million yuan, representing an increase of 278.66 million to 378.66 million yuan compared to the previous year, with a year-on-year growth of 110.87% to 150.66% [2][4] - The company anticipates a net profit attributable to shareholders after deducting non-recurring gains and losses for 2025 to be between 524 million to 624 million yuan, which is an increase of 278.19 million to 378.19 million yuan year-on-year, reflecting a growth of 113.17% to 153.86% [2][4] Group 2 - The performance forecast period is from January 1, 2025, to December 31, 2025 [3] - The previous year's net profit attributable to shareholders was 251.34 million yuan, and the net profit after deducting non-recurring gains and losses was 245.81 million yuan [6] Group 3 - The main reasons for the profit increase include the sustained high prosperity of the refrigerant industry, with price increases driving profit growth. The supply-demand dynamics are expected to remain favorable, with a continued reduction in production quotas for second-generation and third-generation refrigerants [8] - The company benefits from a complete industrial chain layout, which enhances operational efficiency and cost control, while its technological advantages in fluorinated polymer materials continue to translate into competitive products, improving market competitiveness and profitability [9]

Core Insights - Medtronic is positioned to accelerate revenue and earnings growth through engineering, manufacturing, and regulatory expertise [1][2] - The company is focusing on generational growth drivers and a continuous pipeline of new technologies in various medical fields [1] - Medtronic aims to expand margins to increase R&D investment and enhance EPS leverage [2] - Strategic portfolio management and capital allocation are key components of the company's growth strategy [2]

Summary of Medical Device and Healthcare Services Industry Conference Call Industry Overview - The medical device and healthcare services industry is expected to continue its recovery, with long-term investment opportunities emerging for 2026. [1][2] - The impact of centralized procurement is gradually diminishing, with some demand expected to be delayed until 2025. [1][2] Key Insights and Arguments - **Growth Drivers**: The industry is projected to experience steady growth in 2026 due to inventory clearance, new product launches, and growth in overseas markets. [1][2] - **Cautious Outlook from Leading Companies**: Some leading companies have provided cautious performance guidance for the upcoming periods. [1][2] - **Focus Areas**: Specific segments such as orthopedics (e.g., Spring Medical) and e-commerce connections (e.g., New Pulse Medical) are highlighted as areas of interest. [1][3] - **RVD Sector**: The RVD sector is expected to perform well in 2026, driven by a high proportion of overseas revenue (40%). [1][3] - **Electrophysiology**: Companies like Huatai are noted for their cost-effective valuations, with expectations of significant growth driven by new products. [1][5] - **IVD Sector**: The IVD sector is anticipated to face challenges in 2025 but is expected to gradually recover starting in Q4. [1][10] Company-Specific Developments - **Huatai**: Despite recent stock price adjustments, Huatai is expected to see a profit growth rate of over 25% in 2026, supported by the launch of its innovative product TFA. [5] - **Aohua Endoscopy**: The company is expected to see revenue growth due to improved bidding data and the introduction of competitive new products. [6] - **Mindray**: Aiming to penetrate over 2,000 key hospitals in the IVD sector, with potential market share growth due to acquisitions. [11] - **New Industry**: Expected to maintain over 20% growth in overseas markets despite domestic pricing pressures. [11] Investment Opportunities - **Current Market Position**: Many medical device companies, including Mindray and Huatai, are viewed as having long-term value and low valuation opportunities. [7][8] - **Potential High-Growth Companies**: Companies like Microelectrophysiology and Ruimaite are highlighted as having potential for exceeding expectations in business growth. [8] - **2026 Performance Expectations**: The medical device sector is expected to accelerate in 2026, with companies like Mindray and Kaidiya projected to improve performance due to better bidding trends and reduced inventory pressure. [9] Challenges and Risks - **IVD Sector Challenges**: The IVD sector is facing price pressures and a decline in volume in 2025, but is expected to stabilize in 2026. [10] - **High-Value Consumables**: The sector is experiencing challenges due to centralized procurement policies, but opportunities for valuation recovery exist in segments where risks have not fully cleared. [13][14] Future Outlook - **Serious Medical vs. Consumer Medical**: Serious medical is under pressure but expected to recover in the long term, particularly in oncology. Consumer medical is seen as having significant growth potential due to low penetration rates. [19] - **International Expansion**: Domestic companies are increasingly focusing on international markets, with various strategies being employed to enhance their global presence. [17][18] This summary encapsulates the key points discussed in the conference call regarding the medical device and healthcare services industry, highlighting growth prospects, company-specific developments, investment opportunities, and potential challenges.